摘要
目的探讨聚多卡醇联合噻吗洛尔滴眼液治疗婴幼儿血管瘤(infantile hemangioma,IH)的临床效果及安全性。方法选取2017年6月至2019年11月于我院确诊为IH的173例患儿作为研究对象,随机分为3组,对照组A共57例,接受0.5%马来酸噻吗洛尔滴眼液外敷治疗;对照组B共57例,接受1%聚多卡醇泡沫硬化剂瘤内局部注射治疗;观察组共59例,联用对照组A及对照组B的治疗方案。所有患儿结束治疗后,均接受随访6个月。结果观察组总显效率为88.14%,高于对照组A(χ^(2)=38.75,P<0.05),对照组B(χ^(2)=12.27,P<0.05)。观察组总有效率为98.31%,高于对照组A(χ^(2)=8.48,P<0.05),与对照组B无明显统计学差异(χ^(2)=5.06,P>0.05)。对照组B总显效率高于对照组A组(χ^(2)=9.05,P<0.05),总有效率无显著差异(χ^(2)=0.62,P>0.05)。观察组、对照组A、对照组B不良反应发生率分别为5.26%、7.02%、8.47%,组间比较无明显统计学差异(χ^(2)=0.46,P>0.05)。结论聚多卡醇联合噻吗洛尔滴眼液治疗婴幼儿血管瘤效果显著,且不良反应较少,安全性较高。
Objective To explore the clinical efficacy and safety of polydocanol combined with timolol eye drops in the treatment of infantile hemangioma(IH).Methods A total of 173 children with IH diagnosed in our hospital from June 2017 to November 2019 were selected and randomly divided into three groups.57 cases in control group A were treated with 0.5% timolol maleate eye drops.In the control group,57 cases of control group B were treated with local injection of 1% polyol foam sclerotherapy.59 cases in the observation group were treated with control group A and control group B.All patients were followed up for 6 months.Results The total effective rate of observation group was 88.14%,which was higher than that of control group A(χ^(2)=38.75,P<0.05) and control group B(χ^(2)=12.27,P<0.05).The total effective rate of the observation group was 98.31%,which was higher than that of the control group A(χ^(2)=8.48,P<0.05),and there was no significant difference between the two groups(χ^(2)=5.06,P>0.05).The total effective rate of control group B was higher than that of control group A(χ^(2)=9.05,P<0.05),but there was no significant difference in the total effective rate(χ^(2)=0.62,P>0.05).The incidence of adverse reactions in observation group,control group A and control group B were 5.26%,7.02% and 8.47% respectively,and there was no significant difference between the two groups(χ^(2)=0.46,P>0.05).Conclusion Polydocanol combined with timolol eyedrops is effective in treating IH,with fewer adverse reactions and higher safety.
作者
孟令霞
李学荣
MENG Lingxia;LI Xuerong(Medical College of Qingdao University,Qingdao 266071,Shandong Province,China;Department of Neonatology,Changle People's Hospital,Weifang 262400,Shandong Province,China;Department of Pediatric Hematology and Oncology,Affiliated Hospital of Qingdao University,Qingdao 266000,Shandong Province,China)
出处
《世界临床药物》
2021年第6期468-472,500,共6页
World Clinical Drug
